留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

慢性阻塞性肺疾病的药物治疗进展

陈开宇,  江丽萍,  陈盛新

downloadPDF
文章导航 > 药学实践与服务  > 2012 >  30(6): 408-411
陈开宇, 江丽萍, 陈盛新. 慢性阻塞性肺疾病的药物治疗进展[J]. 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
引用本文: 陈开宇, 江丽萍, 陈盛新. 慢性阻塞性肺疾病的药物治疗进展[J]. 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
shu
CHEN Kai-yu, JIANG Li-ping, CHEN Sheng-xin. Progress on drug treatment of chronic obstructive pulmonary disease[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
Citation: CHEN Kai-yu, JIANG Li-ping, CHEN Sheng-xin. Progress on drug treatment of chronic obstructive pulmonary disease[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
shu

慢性阻塞性肺疾病的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2012.06.003

  • 第二军医大学药学院, 上海 200433

Progress on drug treatment of chronic obstructive pulmonary disease

  • School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 摘要: 慢性阻塞性肺疾病作为全球第四大死因,给公众的健康带来了严重威胁。适宜的慢性阻塞性肺疾病药物治疗能够预防和控制症状,减少急性加重的频率和严重程度,提高运动耐力和生活质量。合理使用作用机制不同、作用持续时间不同的药物,是当前慢性阻塞性肺疾病治疗的研究热点。本文综述近年来慢性阻塞性肺疾病的药物治疗进展及其治疗策略。
    Abstract: Chronic obstructive pulmonary disease(COPD), the fourth leading cause of death in the world, represented an important public health challenge. Appropriate medicine therapy in COPD was used to reduce symptoms, the frequency and severity of exacerbations, and improve exercise tolerance and health status. Rational use of the drugs that have different mechanisms, different duration of action was a research focus of COPD. The progress of COPD drug during these years and the strategy of drug treatment were reviewed in this paper.
  • [1] GOLD Executive Committee.Guidelines:Global Strategy for the Diagnosis,Manage-ment,and Prevention of Chronic Obstructive Pulmonary Disease(Revised 2011) [DB/OL],(2011-01-21)[2012-03-18].http://www.goldcopd.org/.
    [2] World Health Organization.The World Health Report 2000-Health systems:improving performance[R/OL]. [2012-03-18]. http://www.who.int/whr/2000/en/index.html.
    [3] Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China:a large, population-based survey[J].Am J Respir Crit Care Med,2007,176:753.
    [4] Lopez AD, Murray CC. The global burden of disease, 1990~2020[J]. Nat Med,1998,4:1241.
    [5] Hogg JC,Chu F,Utokaparch S,et al.The nature of small-airway obstruction in chronic obstructive pulmonary disease[J].N Engl J Med,2004,350:2645.
    [6] Bestall JC,Paul EA,Garrod R,et al.Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease[J].Thorax,1999,54:581.
    [7] Rahman I.Oxidative stress in pathogenesis of chronic obstructive pulmonary disease:cellular and molecular mechanisms[J].Cell Biochem Biophys,2005,43:167.
    [8] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007修订版) [J].中华结核和呼吸杂志,2007,46:254.
    [9] Schols AM,Soeters PB,Dingemans AM,et al.Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation,Am Rev Respir Dis,1993,147:1151.
    [10] 卫生部办公厅.慢性阻塞性肺疾病诊疗规范(2011年版)[EB/OL]. (2011-08-12)[2012-03-18].http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3586/201108/52675.htm.
    [11] COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease,a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial[J]. Chest,1994,105:1411.
    [12] Van Schayck CP,Folgering H,Harbers H,et al.Effects of allergy and age on responses to salbutamol and ipratropium bromide in? moderate asthma and chronic bronchitis[J]. Thorax,1991,46:355.
    [13] Tashkin DP,Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease:current and future agents[J]. Respir Res,2010,11:149.
    [14] Donohue JF,Fabbri C,Lotvall J,et al.Once-daily bronchodilators for chronic obstructive pulmonary disease:indacaterol versus tiotropium[J].Am J Respir Crit Care Med,2010,182:155.
    [15] Casaburi R,Mahler DA,Jones PW,et al.A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease[J].Eur Respir J,2002,19:217.
    [16] 陈新谦,金有豫,汤 光. 新编药物学[M]. 第17版.北京:人民卫生出版社,2011:446.
    [17] Calverley PM,Anderson JA,Celli B,et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J].N Engl J Med,2007,356:775.
    [18] Szafranski W,Cukier A,Ramirez A,et al.Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease[J].Eur Respir J,2003,21:74.
    [19] Rabe KF.Update on roflumilast,a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease[J].Br J Pharmacol,2011,163:53.
    [20] Hansen NC,Skriver A,Brorsen-Riis L,et al.Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis[J].Respir Med,1994,88:531.
    [21] Zheng JP,Kang J,Huang SG,et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study):a randomised placebo-controlled study[J]. Lancet,2008,371,2013.
    [22] 朱 铮. COPD的药物治疗进展[J]. 临床肺科杂志,2011,16:585.
    [23] Jones PW,Harding G,Berry P,et al.Development and first validation of the COPD Assessment Test[J].Eur Respir J, 2009,34:648.
    [24] Hurst JR,Vestbo J,Anzueto A,et al.Susceptibility to exacerbation in chronic obstructive pulmonary disease[J].N Engl Med,2010,363:1128.
    [25] Anthonisen NR,Connett JE,Kiley JP,et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study[J]. JAMA,1994, 272:1497.
    [26] Berry MJ,Rejeski WJ,Adair NE,et al. Exercise rehabilitation and chronic obstructive pulmonary disease stage[J]. Am J Respir Crit Care Med,1999,160:1248.
    [27] Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines:recommendations of the Advisory Committee on Immunization Practices(ACIP),2009[J]. MMWR Recomm Rep,2009,58(RR08):1.
    [28] Hurst JR, Wedzicha JA.The biology of a chronic obstructive pulmonary disease exacerbation[J]. Clin Chest Med,2007,28:525.
    [29] Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations[J]. Am J Respir Crit Care Med,2006,173:1114.
    [30] Hurst JR, Wedzicha JA. Management and prevention of chronic obstructive pulmonary disease exacerbations:a state of the art review[J]. BMC Med,2009,7:40.
  • [1] 段虎, 周艳卿, 钱瑜琳, 赵亮.  某二级医院稳定期慢性阻塞性肺疾病患者吸入治疗依从性及其影响因素 . 药学实践与服务, 2024, 42(3): 1-5. doi: 10.12206/j.issn.2097-2024.202204094
    [2] 陈丹, 刘国栋, 刘煜, 童少华, 刘胜军.  咳喘医药联合门诊服务模式的实践与探索 . 药学实践与服务, 2023, 41(11): 689-693. doi: 10.12206/j.issn.2097-2024.202209034
    [3] 王洁, 卞莹莹, 张川, 开国银, 陆一鸣.  肿瘤坏死因子及其受体在类风湿性关节炎中的研究进展 . 药学实践与服务, 2017, 35(4): 289-293. doi: 10.3969/j.issn.1006-0111.2017.04.001
    [4] 张晋萍, 张海霞, 徐航, 卞晓洁, 杨贤, 方芸.  临床药师参与141例感染性疾病会诊的分析与体会 . 药学实践与服务, 2017, 35(1): 89-93. doi: 10.3969/j.issn.1006-0111.2017.01.023
    [5] 雷永芳, 凌青.  良性前列腺增生症的药物治疗及个体化用药 . 药学实践与服务, 2017, 35(5): 447-448,456. doi: 10.3969/j.issn.1006-0111.2017.05.015
    [6] 卞莹莹, 王洁, 李安, 开国银, 陆一鸣.  炎症性肠病的药物治疗现状 . 药学实践与服务, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
    [7] 罗志成, 吴国振, 袁星.  慢性阻塞性肺疾病治疗药物研究进展 . 药学实践与服务, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003
    [8] 马宗强, 安洪亮.  门诊口服抗高血压药物的调查分析 . 药学实践与服务, 2016, 34(2): 188-190,192. doi: 10.3969/j.issn.1006-0111.2016.02.024
    [9] 赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕.  神经病理性疼痛的药物治疗进展 . 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
    [10] 赵柳娅, 曹颖瑛, 姜远英.  两性霉素B联合用药的研究进展 . 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
    [11] 陈翊, 濮剑英.  噻托溴铵对中重度慢性阻塞性肺病的治疗效果 . 药学实践与服务, 2012, 30(3): 213-215. doi: 10.3969/j.issn.1006-0111.2012.03.015
    [12] 丁晴雪, 栾智鹏, 陈盛新.  如何制定、实施和监测药物治疗方案 . 药学实践与服务, 2009, 27(4): 317-320.
    [13] 冯惠坚, 栾智鹏, 陈盛新.  医院药师如何开展循证药物治疗 . 药学实践与服务, 2009, 27(6): 476-480.
    [14] 傅翔, 栾智鹏, 陈盛新.  用药安全 . 药学实践与服务, 2009, 27(3): 236-240.
    [15] 赵民生, 曹秀虹.  利尿剂在治疗心血管疾病时的不良反应及处理 . 药学实践与服务, 2006, (6): 353-354.
    [16] 张虹.  复方溶石剂一号的效果及安全性评价 . 药学实践与服务, 2005, (1): 24-27.
    [17] 徐国华, 雷招宝.  治疗慢性丙型肝炎新药——聚乙二醇干扰素α-2b . 药学实践与服务, 2005, (6): 350-353.
    [18] 唐斌, 何佩珍, 徐帆, 尚北城.  黄连素的联合用药 . 药学实践与服务, 2005, (5): 278-281.
    [19] 张生大.  双嘧达莫与其它药物合用的新用途 . 药学实践与服务, 2001, (1): 13-13.
    [20] 张铁俊, 张小莉, 王东文.  消化性溃疡临床用药 . 药学实践与服务, 1999, (2): 82-85.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  15025
  • HTML全文浏览量:  617
  • PDF下载量:  2648
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-03-02
  • 修回日期:  2012-05-28

慢性阻塞性肺疾病的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2012.06.003
  • 第二军医大学药学院, 上海 200433
  • 收稿日期: 2012-03-02
  • 修回日期: 2012-05-28

摘要: 慢性阻塞性肺疾病作为全球第四大死因,给公众的健康带来了严重威胁。适宜的慢性阻塞性肺疾病药物治疗能够预防和控制症状,减少急性加重的频率和严重程度,提高运动耐力和生活质量。合理使用作用机制不同、作用持续时间不同的药物,是当前慢性阻塞性肺疾病治疗的研究热点。本文综述近年来慢性阻塞性肺疾病的药物治疗进展及其治疗策略。

English Abstract

陈开宇, 江丽萍, 陈盛新. 慢性阻塞性肺疾病的药物治疗进展[J]. 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
引用本文: 陈开宇, 江丽萍, 陈盛新. 慢性阻塞性肺疾病的药物治疗进展[J]. 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
shu
CHEN Kai-yu, JIANG Li-ping, CHEN Sheng-xin. Progress on drug treatment of chronic obstructive pulmonary disease[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
Citation: CHEN Kai-yu, JIANG Li-ping, CHEN Sheng-xin. Progress on drug treatment of chronic obstructive pulmonary disease[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
shu

    全文HTML

参考文献 (30)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计